Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Paratek antibiotic not inferior to current treatments: FDA staff

U.S. FDA staff reviewers said Paratek Pharmaceuticals Inc.’s potential new antibiotic is not inferior to current treatments.

Read More »

Nabriva’s pneumonia drug succeeds in late-stage trial

Nabriva Therapeutics’ experimental antibiotic lefamulin for CABP met the main goal of a late-stage study.

Read More »

Troubled Cempra Slashes 67 Percent of Workforce

Antibiotic drugmaker Cempra Inc. will terminate 67 percent of its employees following the U.S. FDA’s rejection of solithromycin, an oral and intravenous drug being evaluated for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

Read More »

FDA rejects Cempra’s antibiotic for pneumonia

The FDA rejected Cempra Inc.’s antibiotic for community-acquired bacterial pneumonia, citing inadequate data on the drug’s impact on liver and manufacturing issues.

Read More »

Cempra’s experimental antibiotic succeeds in late-stage study

Cempra Inc moved a step closer to approval of its lead antibiotic after the potential blockbuster was successful in a second late-stage trial in patients with a common bacterial infection. Data announced in January had showed that the oral version of the drug was successful in a separate late-stage study in patients with community-acquired bacterial […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom